Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis.
Peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors that regulate cellular energy and lipid metabolism. PPAR-gamma agonists also have potent anti-inflammatory properties through down-regulation of early inflammatory response genes. The role of PPAR-gamma in acute pancreatitis has not been adequately examined. In this study, we determined the effect of PPAR-gamma agonists on the severity of pancreatitis and sought to correlate PPAR-gamma expression in pancreatic acinar cells and the severity of acute pancreatitis in vivo. Acute pancreatitis was induced in mice by hyperstimulation with the cholecystokinin analog, cerulein. PPAR-gamma agonists were administered by intraperitoneal injection 15-30 minutes before induction of pancreatitis (pretreatment) or at various times after induction of pancreatitis (treatment). Pancreata and serum were harvested over the course of 24 hours. Serum amylase activity and glucose levels were measured. Pancreata were used for histological evaluation as well as protein and mRNA analysis. Pretreatment of mice with the PPAR-gamma agonists 15-deoxy-Delta12, 14-prostaglandin J(2), or troglitazone significantly reduced the severity of pancreatitis in a dose-dependent manner. This reduction was indicated by reduced serum amylase activity and histological damage (leukocyte infiltration, vacuolization, and necrosis). Although cerulein decreased PPAR-gamma expression in the pancreas, pretreatment with agonists maintained PPAR-gamma expression early in acute pancreatitis. The expression of PPAR-gamma inversely correlated with pancreatitis severity and expression of the proinflammatory cytokines, interleukin-6, and tumor necrosis factor-alpha. Treatment with troglitazone after the induction of pancreatitis reduced serum amylase activity. The results suggest that PPAR-gamma plays a direct role in the inflammatory cascade during the early events of acute pancreatitis. Our data are the first to demonstrate that PPAR-gamma agonists represent a promising therapeutic strategy for acute pancreatitis.
Rollins
Michael D
MD
Department of Surgery, University of Utah School of Medicine, Salt Lake City, Utah 84132, USA.
Sudarshan
Sharon
S
Firpo
Matthew A
MA
Etherington
Brooke H
BH
Hart
Brandon J
BJ
Jackson
Heidi H
HH
Jackson
Jeffrey D
JD
Emerson
Lyska L
LL
Yang
David T
DT
Mulvihill
Sean J
SJ
Glasgow
Robert E
RE
D000818:Animals; D015153:Blotting, Western; D002108:Ceruletide / Q000633:toxicity; D002839:Chromans / Q000627:therapeutic use; D004195:Disease Models, Animal; D005500:Follow-Up Studies; D015870:Gene Expression; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D047495:PPAR gamma / Q000819:agonists / Q000097:blood / Q000235:genetics; D019283:Pancreatitis, Acute Necrotizing / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D015230:Prostaglandin D2 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012720:Severity of Illness Index; D045162:Thiazolidinediones / Q000627:therapeutic use; D016896:Treatment Outcome; D000077288:Troglitazone; D014665:Vasodilator Agents / Q000627:therapeutic use
C477819:15-deoxyprostaglandin J2; D002839:Chromans; D047495:PPAR gamma; D012333:RNA, Messenger; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D002108:Ceruletide; D000077288:Troglitazone; D015230:Prostaglandin D2